311 related articles for article (PubMed ID: 23261227)
1. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT.
Choi H; Paeng JC; Kim DW; Lee JK; Park CM; Kang KW; Chung JK; Lee DS
Lung Cancer; 2013 Mar; 79(3):242-7. PubMed ID: 23261227
[TBL] [Abstract][Full Text] [Related]
2. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.
Choi CM; Kim MY; Hwang HJ; Lee JB; Kim WS
Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117
[TBL] [Abstract][Full Text] [Related]
3. Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma.
Jeong CJ; Lee HY; Han J; Jeong JY; Lee KS; Choi YL; Choi JY
Clin Nucl Med; 2015 Jan; 40(1):e34-9. PubMed ID: 25243942
[TBL] [Abstract][Full Text] [Related]
4. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
[TBL] [Abstract][Full Text] [Related]
5. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
6. Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations.
Kim TJ; Lee CT; Jheon SH; Park JS; Chung JH
Ann Thorac Surg; 2016 Feb; 101(2):473-80. PubMed ID: 26454747
[TBL] [Abstract][Full Text] [Related]
7. SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer.
Putora PM; Szentesi K; Glatzer M; Rodriguez R; Müller J; Baty F; Früh M
Oncol Res Treat; 2016; 39(11):681-686. PubMed ID: 27855379
[TBL] [Abstract][Full Text] [Related]
8. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.
Yip PY; Yu B; Cooper WA; Selinger CI; Ng CC; Kennedy CW; Kohonen-Corish MR; McCaughan BC; Trent RJ; Boyer MJ; Kench JG; Horvath LG; O'Toole SA
J Thorac Oncol; 2013 Apr; 8(4):408-14. PubMed ID: 23392229
[TBL] [Abstract][Full Text] [Related]
9. The value of ultrasound-guided biopsy of fluorodeoxy-glucose positron emission tomography (FDG-PET)-positive supraclavicular lymph nodes in patients with suspected lung cancer.
Werner L; Keller FA; Bhure U; Roos JE; Tornquist K; Del Sol Pèrez-Lago M; Gautschi O; Strobel K
BMC Med Imaging; 2017 Jul; 17(1):41. PubMed ID: 28693444
[TBL] [Abstract][Full Text] [Related]
10. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
Lee EY; Khong PL; Lee VH; Qian W; Yu X; Wong MP
Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
12. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations.
Zhou JY; Zheng J; Yu ZF; Xiao WB; Zhao J; Sun K; Wang B; Chen X; Jiang LN; Ding W; Zhou JY
Eur Radiol; 2015 May; 25(5):1257-66. PubMed ID: 25577516
[TBL] [Abstract][Full Text] [Related]
14. F-18 FDG uptake on positron emission tomography as a predictor for lymphovascular invasion in patients with lung adenocarcinoma.
Noda Y; Goshima S; Kanematsu M; Watanabe H; Kawada H; Kawai N; Ono H; Bae KT
Ann Nucl Med; 2016 Jan; 30(1):11-7. PubMed ID: 26337532
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients.
Wang WY; Liang DN; Yao WQ; Wu WL; Li JN; Chen M; Liao DY; Zhang M; Li GD
Hum Pathol; 2014 Jul; 45(7):1414-22. PubMed ID: 24775606
[TBL] [Abstract][Full Text] [Related]
16. Value of
Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
[TBL] [Abstract][Full Text] [Related]
17. [Positron emission tomography/computed tomography for lung cancer staging].
Ladrón de Guevara H D; Furnaro L F; Yévenes A S; Clavero R JM; Lazo P D; Rodríguez D P; Piottante B A; Pefaur D R; Pardo B C
Rev Med Chil; 2015 Jan; 143(1):22-9. PubMed ID: 25860265
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan.
Guan J; Chen M; Xiao N; Li L; Zhang Y; Li Q; Yang M; Liu L; Chen L
Med Oncol; 2016 Jan; 33(1):1. PubMed ID: 26589606
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.
Koh Y; Kim DW; Kim TM; Lee SH; Jeon YK; Chung DH; Kim YW; Heo DS; Kim WH; Bang YJ
J Thorac Oncol; 2011 May; 6(5):905-12. PubMed ID: 21358343
[TBL] [Abstract][Full Text] [Related]
20. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
